MX2017016774A - Agente terapeutico para la fibrosis. - Google Patents

Agente terapeutico para la fibrosis.

Info

Publication number
MX2017016774A
MX2017016774A MX2017016774A MX2017016774A MX2017016774A MX 2017016774 A MX2017016774 A MX 2017016774A MX 2017016774 A MX2017016774 A MX 2017016774A MX 2017016774 A MX2017016774 A MX 2017016774A MX 2017016774 A MX2017016774 A MX 2017016774A
Authority
MX
Mexico
Prior art keywords
fibrosis
therapeutic agent
amino
therapeutic
thioxomethyl
Prior art date
Application number
MX2017016774A
Other languages
English (en)
Inventor
Fujioka Akio
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MX2017016774A publication Critical patent/MX2017016774A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4

Abstract

Se proveen un agente terapéutico y una composición farmacéutica que exhiben excelente efecto profiláctico o terapéutico contra la fibrosis o los síntomas asociados con la fibrosis; este agente terapéutico para la fibrosis contiene 4-[ 2-fluoro-4-[[[(2- fenilacetil)amino]tioxometil]amino]-fenoxi]-7-metoxi-N-metil-6-qu inolincarboxamida o una sal de la misma como un ingrediente activo.
MX2017016774A 2015-06-25 2016-06-24 Agente terapeutico para la fibrosis. MX2017016774A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015127788 2015-06-25
PCT/JP2016/068902 WO2016208744A1 (ja) 2015-06-25 2016-06-24 線維症治療剤

Publications (1)

Publication Number Publication Date
MX2017016774A true MX2017016774A (es) 2018-05-14

Family

ID=57585165

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017016774A MX2017016774A (es) 2015-06-25 2016-06-24 Agente terapeutico para la fibrosis.
MX2020012989A MX2020012989A (es) 2015-06-25 2017-12-19 Agente terapeutico para la fibrosis.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020012989A MX2020012989A (es) 2015-06-25 2017-12-19 Agente terapeutico para la fibrosis.

Country Status (21)

Country Link
US (4) US10449189B2 (es)
EP (2) EP3315131B1 (es)
JP (3) JP6974167B2 (es)
KR (1) KR102647942B1 (es)
CN (2) CN112716952A (es)
AU (1) AU2016284531B2 (es)
BR (1) BR112017028137B1 (es)
CA (1) CA2990791A1 (es)
DK (1) DK3315131T3 (es)
ES (1) ES2928684T3 (es)
HK (1) HK1245639A1 (es)
HU (1) HUE060732T2 (es)
MA (1) MA42266A (es)
MX (2) MX2017016774A (es)
MY (1) MY191219A (es)
PH (1) PH12017502322A1 (es)
PL (1) PL3315131T3 (es)
PT (1) PT3315131T (es)
RU (1) RU2729630C2 (es)
SG (2) SG11201709260TA (es)
WO (1) WO2016208744A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8324454B2 (en) 2006-03-14 2012-12-04 Ceres, Inc. Nucleotide sequences and corresponding polypeptides conferring modulated growth rate and biomass in plants grown in saline conditions
MX2021007061A (es) 2017-02-15 2022-10-07 Taiho Pharmaceutical Co Ltd Composición farmacéutica que comprende 4-(2-fluoro-4-(3-(2- fenilacetil)tioureido)fenoxi)-7-metoxi-n-metilquinolina-6-carboxa mida e hidroxipropil-b-ciclodextrina.
WO2020059744A1 (ja) 2018-09-18 2020-03-26 大鵬薬品工業株式会社 アシルチオウレア化合物とアビラテロンの併用療法
TW202140426A (zh) * 2020-02-14 2021-11-01 日商大鵬藥品工業股份有限公司 醯基硫脲化合物的製造方法
CN115177636A (zh) * 2022-07-18 2022-10-14 陕西科美致尚生物科技有限公司 一种用于治疗前列腺钙化的组合物及其制备方法与应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999055361A1 (fr) 1998-04-28 1999-11-04 Toshikazu Nakamura Inhibiteurs de neovascularisation
JP2003238592A (ja) 2001-12-13 2003-08-27 Japan Tobacco Inc 組織及び血管の再生のための医薬及びその方法
JP2009500347A (ja) 2005-06-30 2009-01-08 アムジエン・インコーポレーテツド ビスアリールキナーゼ阻害剤及びこれらの炎症、血管新生及び癌の治療における使用
ZA200804681B (en) * 2005-11-30 2009-11-25 Vertex Pharma Inc Inhibitors of C-Met and uses thereof
BRPI0619252A2 (pt) 2005-11-30 2011-09-20 Vertex Pharma inibidores de c-met e seus usos
MX2009008531A (es) 2007-02-16 2009-08-26 Amgen Inc Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
CA2703653A1 (en) * 2007-10-25 2009-04-30 Astrazeneca Ab Pyridine and pyrazine derivatives -083
AU2009234978B2 (en) 2008-04-10 2014-03-06 Taiho Pharmaceutical Co., Ltd. Acylthiourea Compound or Salt Thereof, and use thereof
UY32049A (es) * 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
EA025304B1 (ru) * 2010-02-03 2016-12-30 Инсайт Холдингс Корпорейшн ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИНЫ В КАЧЕСТВЕ c-Met ИНГИБИТОРОВ
CN107674073B (zh) 2010-05-17 2021-09-10 印蔻真治疗公司 作为蛋白激酶调节剂的3,5-二取代-3h-咪唑(或[1,2,3]三唑)并[4,5-b] 吡啶化合物
TWI594986B (zh) 2011-12-28 2017-08-11 Taiho Pharmaceutical Co Ltd Antineoplastic agent effect enhancer
RU2494470C1 (ru) * 2012-04-04 2013-09-27 Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "Саентифик Фьючер Менеджмент") Способ лечения фиброза легких
US9149471B2 (en) 2013-09-30 2015-10-06 National University Corporation Tokyo University Of Agriculture And Technology Therapeutic agent for osteoporosis

Also Published As

Publication number Publication date
EP3315131A1 (en) 2018-05-02
ES2928684T3 (es) 2022-11-21
PL3315131T3 (pl) 2022-12-12
HUE060732T2 (hu) 2023-04-28
DK3315131T3 (da) 2022-11-14
PH12017502322A1 (en) 2018-06-25
US20200009128A1 (en) 2020-01-09
EP3973962A1 (en) 2022-03-30
EP3315131A4 (en) 2019-02-27
JP6974167B2 (ja) 2021-12-01
PT3315131T (pt) 2022-10-26
RU2017145271A3 (es) 2019-12-02
US20180289690A1 (en) 2018-10-11
US10695340B2 (en) 2020-06-30
WO2016208744A1 (ja) 2016-12-29
CN107708697A (zh) 2018-02-16
MY191219A (en) 2022-06-09
US20220047572A1 (en) 2022-02-17
JP2023076632A (ja) 2023-06-01
JP7258985B2 (ja) 2023-04-17
KR20180021682A (ko) 2018-03-05
BR112017028137B1 (pt) 2023-04-04
AU2016284531B2 (en) 2020-06-04
CA2990791A1 (en) 2016-12-29
US10449189B2 (en) 2019-10-22
SG11201709260TA (en) 2018-01-30
RU2729630C2 (ru) 2020-08-11
HK1245639A1 (zh) 2018-08-31
BR112017028137A2 (pt) 2018-08-28
JP2022009994A (ja) 2022-01-14
RU2017145271A (ru) 2019-07-25
CN112716952A (zh) 2021-04-30
KR102647942B1 (ko) 2024-03-14
SG10201912684TA (en) 2020-03-30
JPWO2016208744A1 (ja) 2018-04-12
EP3315131B1 (en) 2022-09-14
AU2016284531A1 (en) 2017-11-30
MA42266A (fr) 2018-05-02
US11690838B2 (en) 2023-07-04
US11191759B2 (en) 2021-12-07
CN107708697B (zh) 2021-02-09
US20200297716A1 (en) 2020-09-24
MX2020012989A (es) 2021-02-16

Similar Documents

Publication Publication Date Title
MX2016016593A (es) Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos.
MX2020012989A (es) Agente terapeutico para la fibrosis.
NZ763551A (en) Compounds useful for inhibiting cdk7
MY187047A (en) Selective pyy compounds and uses thereof
WO2015070224A3 (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
PH12017501084A1 (en) Insulin glargine/lixisenatide fixed ratio formulation
MX2021008432A (es) Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
MX2016001422A (es) Composicion farmaceutica de fingolimod.
PH12018500358A1 (en) Compounds for use in an antibacterial applications
MY183068A (en) Pharmaceutical formulation comprising antibody
MX2019008338A (es) Composicion farmaceutica que contiene sulglicotido o una sal farmaceuticamente aceptable del mismo para la prevencion o tratamiento del ojo seco.
PH12018501758A1 (en) Oritavancin formulations
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
MX2015013151A (es) Métodos de tratamiento de disquinesia y trastornos relacionados.
PH12018500579A1 (en) Fungal keratitis prophylactic or therapeutic agent
WO2018074880A3 (ko) 퀴놀린 4-온 유도체 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 폐렴의 예방 또는 치료용 약학적 조성물
EP3404020A4 (en) PYRIDINOL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT
MX2017008879A (es) Composicion farmaceutica para el tratamiento de la micosis.
PH12018501991A1 (en) Pharmaceutical composition for use in treating fibrosis
EP3624809A4 (en) PHARMACEUTICAL AGENTS, COMPOSITIONS AND RELATED PROCESSES
WO2017210527A8 (en) Autotaxin inhibitors
TR201721065A2 (tr) Deksmedetomi̇di̇n i̇çeren li̇yofi̇li̇ze farmasöti̇k formülasyonlar
PH12020500510A1 (en) Prophylactic and/or therapeutic agent for diseases involving ido expression